Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community
Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community
ATLANTA – February 20, 2025- Today, Invest Atlanta announced, the city of Atlanta has been designated a BioReady Gold Community by the state’s leading life sciences membership organization, Georgia Life Sciences. To receive this distinction, communities must meet certain criteria related to zoning practices and infrastructure capacity. This distinctive honor was presented today during Invest Atlanta’s February board of directors meeting.
“We are proud to recognize the City of Atlanta as a BioReady site, as much of our life sciences ecosystem is built around the state’s capital city,” said Maria Thacker-Goethe, President and CEO of Georgia Life Sciences. “Through this program, we champion communities that have made a commitment to growing the life sciences industry, helping to distinguish the state with not only a significant presence of leading biopharma companies and startups, but also with robust funding opportunities to fuel growth, and a collaborative environment with access to resources and infrastructure.”
The BioReady rating system rates communities in three tiers from Bronze to Silver to Gold. Through these BioReady ratings, Georgia Life Sciences allows local municipalities to better showcase biotech-zoned science parks, streamline permitting, build a robust infrastructure, and identify biotech-friendly sites more effectively, making them a desirable choice for real estate developers and biotechnology companies seeking destinations to locate.
“We are thrilled to witness our city being recognized as a BioReady Gold Community, a testament to our commitment to innovation and sustainability in the life sciences,” said Atlanta Mayor Andre Dickens. This acknowledgment not only highlights our readiness but also paves the way for future growth and collaboration in the bioscience sector. This designation affirms Atlanta’s readiness to support biotech companies and reinforces our position as a hub for scientific innovation.”
“According to BioSpace, the global life sciences market is valued at $13.72 billion and is projected to reach $26.63 billion by 2033,” said Dr. Eloisa Klementich, president and CEO of Invest Atlanta. Earning BioReady Gold status strengthens our efforts to attract and retain biotech and life sciences companies. With the Life Sciences workforce expected to grow 10% from 2022 to 2032, this recognition reinforces Invest Atlanta’s commitment to biotech and life sciences, giving companies confidence in our support and resources.”
For more information about this recognition visit, BioReady Communities.
About Georgia Life Sciences
Georgia Life Sciences, founded in 1989, is a non-profit, membership-based organization that promotes the interests and growth of the life sciences industry. It is the state’s largest and most influential life sciences advocacy and business leadership organization working to improve access to innovative discoveries that have lifesaving impact. The association connects business, academia, government, and other allied entities involved in the application of life sciences products to fuel growth and collaboration through policy development, community programs, national industry initiatives, and a portfolio of educational and networking events. Learn more at www.galifesciences.org.
“Evolving FTC and DOJ policies leave investors and innovators navigating a cautious M&A landscape
Atlanta, GA — October 6 — Georgia Life Sciences today announced the launch of Vitals, a new podcast series developed in partnership with Cloudcast Media, a leader in branded podcast production. The series will spotlight the people, ideas, and innovations shaping the future of Georgia’s rapidly growing life sciences sector. Hosted by Georgia Life Sciences’ CEO, Maria Thacker Goethe, Vitals will feature in-depth conversations with scientists, entrepreneurs, investors, educators, policymakers, and patient advocates. Each episode will explore the challenges and opportunities facing Georgia’s life sciences ecosystem—spanning biopharma, medical technology, digital health, and advanced manufacturing. “Vitals gives us a powerful platform to showcase the remarkable work happening within our state,” said Maria Thacker Goethe. “By sharing these stories, we’re highlighting not only groundbreaking science but also the collaboration and talent that make Georgia such a vibrant hub for health innovation.” Cloudcast Media, known for its expertise in storytelling and high-quality podcast production, will bring industry insights and technical support to ensure the series reaches audiences across Georgia and beyond. “We’re proud to partner with Georgia Life Sciences on Vitals,” said Charles Parisi, Founder and CEO of Cloudcast. “This series will elevate the voices of innovators who are advancing science, improving patient outcomes, and building Georgia’s reputation as a global life sciences leader. We are very excited that Cloudcast Atlanta can play a role in supporting Maria and the impactful work of Georgia Life Sciences.” The first episode of Vitals launched today and is available on Apple Podcasts, Spotify, and other major streaming platforms, as well as through the Georgia Life Sciences website.
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###
